Updated
Updated · mg Magazine · Aug 12
Curaleaf Plans $4-a-Share Bid for Aurora, Taking 0.3463 Shares Plus $0.75 Directly to Holders
Updated
Updated · mg Magazine · Aug 12

Curaleaf Plans $4-a-Share Bid for Aurora, Taking 0.3463 Shares Plus $0.75 Directly to Holders

3 articles · Updated · mg Magazine · Aug 12

Summary

  • Curaleaf said it intends to make an unsolicited offer for all Aurora shares, valuing the proposal at an implied US$4 per share, capped at US$5 if Curaleaf stock rises sharply before take-up.
  • Aurora said no formal bid has begun and disputed Curaleaf’s claim that it had been stonewalled, saying only a July 7 letter included financial terms and that its lead independent director stayed in contact with Curaleaf through July 24.
  • Aurora is forming a special committee of independent directors rather than rejecting the approach outright, leaving open whether the campaign turns into a negotiated deal or fails to win enough shareholder support.
  • Aurora shares closed at US$3.48 after the dueling announcements, up about 20% from US$2.89 but still below Curaleaf’s stated value, signaling investors see meaningful execution risk.
  • CAD$149.1 million of cash and no debt give Aurora room to deliberate despite a 9% revenue decline, while past Canadian cannabis hostile bids have split between Aurora’s successful sweetened CanniMed pursuit and Green Growth’s failed Aphria bid.

Insights

Can Curaleaf actually finance its aggressive bid for Aurora, or is the strict price cap a fatal flaw for shareholders?
Will Curaleaf’s hostile takeover secure Europe’s medical cannabis crown, or will Aurora’s pushback derail the mega-merger?